Search the Newsreel

Legend Biotech (NASDAQ:LEGN) Shares Gap Up After Strong Earnings

Avecho Biotechnology Limited (ASX:AVE) Share Market Overview and Biotechnology Sector Profile

Legend Biotech Q2 Earnings Call Highlights

Key Points Interested in Legend Biotech Corporation Sponsored ADR? Here are five stocks we like better. CARVYKTI sales rose sharply: Worldwide net trade sales increased 50% year over year to approximately $657 million, driven by earlier-line treatment adoption in the U.S. and international expansion …

Earnings call transcript: Legend Biotech tops Q2 2026 estimates as stock rises 5%

Legend Biotech reported stronger-than-expected Q2 2026 results, achieving its first quarter of company-wide profitability with adjusted earnings of $0.16 per share and revenue of $387.5 million, significantly beating analyst estimates. The company's lead CAR-T therapy, CARVYKTI, saw worldwide net trade sales increase 50% year-over-year, …

Genscript Highlights Legend Biotech’s Q2 Results and Cautions Investors

Form 8K PDS Biotechnology Corp For: 11 August By Investing.com

This article announces the filing of a Form 8K by PDS Biotechnology Corp for August 11, as reported by Investing.com. It provides a brief update on company filings without further details on the content of the Form 8K. The article appears to be a …

PDS0301 Data Show 80% 24-Month Survival With Liver Metastases

PDS Biotechnology (Nasdaq: PDSB) announced a strategic refocus, prioritizing its tumor-targeted IL-12 immunocytokine PDS0301 and discontinuing internal investment in the PDS0101 Phase 3 VERSATILE-003 trial, instead seeking strategic partnerships for PDS0101. This decision follows promising Phase 2 data for PDS0301 in metastatic colorectal cancer …

Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The CEO who helped guide development of the top-selling cell therapy for multiple myeloma will take the reins of a young startup …

Legend Biotech stock rises 5% on earnings and revenue beat

Pipette dropping liquid into a test tube ©Adobe Stock Images Legend Biotech Corporation (NASDAQ:LEGN) shares gained 5.5% in pre-market trading on Tuesday after the pharmaceutical company delivered better-than-expected second-quarter earnings and revenue, supported by continued growth in CARVYKTI sales. Adjusted earnings came in at …

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

Legend Biotech USA Inc. CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 million Expanded CARVYKTI® availability to 348 global sites and 19 global markets with the launch of Ireland Achieved first clinical proof-of-concept for LB2501, …

Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Navigating the Growth Path with a 21.5% Revenue Surge

Adaptive Biotechnologies Corp (ADPT) is a commercial-stage company leveraging its immune medicine platform for diagnostics and treatment, showing a 21.5% revenue growth. Despite current losses and a negative Forward P/E, the company has a strong market capitalization of $4.05 billion and positive analyst sentiment …

Why Did Adaptive Biotechnologies (ADPT) Move After Its Latest Update?

Adaptive Biotechnologies stock hits 52-week high at 25.04 USD By Investing.com

Adaptive Biotechnologies (ADPT) stock has reached a 52-week high of $25.04, reflecting a 104% increase over the past year and underscoring strong performance in the biotechnology sector. The company's market capitalization is now $3.95 billion, with 50% revenue growth, indicating strong investor confidence. This …

Windlas Biotech Standalone June 2026 Net Sales at Rs 248.10 crore, up 18.09% Y-o-Y

Veraxa Biotech AG Ord Shs (VRXA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Veraxa Biotech AG Ord Shs (VRXA), detailing its future EPS and Revenue Growth Estimates. It includes current stock performance data, market capitalization, and a peer comparison with other biotechnology and medical research companies. The financial forecasting sections …

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages

Vir Biotechnology, Inc. (NASDAQ:VIR) has an average "Moderate Buy" rating from analysts, with a consensus 12-month price target of $20.63, significantly higher than its current price of $8.89. The company recently reported strong quarterly earnings, beating revenue and EPS estimates, despite a negative net …

Earnings Flash (LEGN) Legend Biotech Corporation Posts Q2 Adjusted Net Income $0.16 per Share

Legend Biotech Corporation reported an adjusted net income of $0.16 per share for the second quarter of 2026. This financial announcement was made on August 11, 2026, and also included a reported Q2 revenue of $387.5 million, surpassing FactSet's estimate of $356.0 million. The …

Nautilus Biotechnology (NAUT) Slides 3.9% to $0.86, Approaching Key Support Level - Liquidity Order Flow

MBRX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage Investment - Low Growth Earnings

SANA Q2 2026 Earnings: Narrower-than-Expected Loss Highlights Capital Discipline - Earnings Surprise Report

SANA Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 3.19% - Revenue Guidance Range

PharmaCyte Biotech (PMCB) Climbs to $0.55 as Micro-Cap Biotech Holds Key Support - Earnings Breakout Stocks

Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Hong Kong Market Midday Commentary | All three major indices declined, with the Hang Seng Tech Index down 1.27%; tech and internet stocks fell, with Kuaishou and JD.com each dropping nearly 3%; biotech stocks rose, as GenScript Biotech surged over 8

Sana Biotechnology | 10-Q: Quarterly report

This document is a 10-Q Quarterly Report filed by Sana Biotechnology. It provides a formal financial and operational update for the quarter.

Purple Biotech Unveils August 2026 Corporate Update on Tri-Specific Immuno-Oncology Platform

Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript

Krystal Biotech (KRYS) reported strong Q2 2026 results, with net product revenue up 24% to $119.2 million, driven by VYJUVEK sales and expansion into community settings. The company achieved 730+ U.S. reimbursement approvals and is advancing a robust clinical pipeline, including registrational studies for …

If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today

Krystal Biotech (NASDAQ: KRYS) has significantly outperformed the market over the last five years, with an average annual return of 42.63%. An initial investment of $1000 in KRYS five years ago would now be worth $5,893.89, demonstrating the power of compounded returns. The company …

Puma Biotechnology, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-08-10

Puma Biotechnology reported strong Q2 2026 financial results, with total revenue reaching $56.5 million, primarily driven by increased demand for NERLYNX. The company is now debt-free after repaying its Athyrium loan and has raised its full-year guidance for both product revenue and net income. …

Sana Biotechnology Q2 Results: Adj. EPS beats estimate

Sana Biotechnology reported stronger-than-expected Q2 2026 results, with non-GAAP EPS of $(0.13) surpassing analyst estimates. The company secured $93.3 million in new funding, increasing its cash reserves to $160.5 million and extending its financial runway until mid-2027. This financial stability supports the advancement of …

Sana Biotechnology falls 5% despite beating earnings estimates

Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results

Sana Biotechnology (NASDAQ:SANA) reported a quarterly loss of $0.13 per share, surpassing the consensus estimate of a $0.15 loss. Following the announcement, SANA shares increased by 2.6% to $3.61. The company holds a "Moderate Buy" consensus rating from analysts with an average price target …

Sana Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary

ADPT (ADPT) insider outlines Form 144 sale of 3,000 shares

A holder of Adaptive Biotechnologies Corp (ADPT) common stock has filed a Form 144, indicating an intention to sell 3,000 shares valued at $74,790.00 through Morgan Stanley Smith Barney. These shares are Restricted Stock Units acquired from the issuer on March 4, 2023. The …

Sana Biotechnology (SANA) warns on going concern amid $110.8M loss

Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q2 Adjusted Loss $0.13 per Share, vs. FactSet Est of $-0.12

Sana Biotechnology, Inc. (SANA) reported a Q2 adjusted loss of $0.0.13 per share, which was narrower than the FactSet estimate of a $0.12 loss per share. The company focuses on developing engineered cells as medicines for therapeutic areas such as type 1 diabetes, oncology, …